Figure 2 | Scientific Reports

Figure 2

From: The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma

Figure 2

Cytotoxicity of proteasome inhibitors in combination with nelfinavir in NSCLC patient-derived primary cells. Primary cells derived from surgically resected tumors and adjacent healthy tissue from NSCLC patients were isolated, characterized by flow cytometry and subjected to cytotoxicity assays. The cells were exposed to bortezomib (nM), carfilzomib (nM) and nelfinavir (µM) in monotherapy or in combination continuously for 48 h. (A–C): adenocarcinoma and adjacent healthy lung tissue; (D) squamous cell carcinoma without adjacent healthy lung tissue.

Back to article page